UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 23, 2018
Allena Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-38268 | 45-2729920 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| One Newton Executive Park, Suite 202 Newton, Massachusetts |
02462 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code (617) 467-4577
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 23, 2018, Mr. Stephen Kraus, a member of the Board of Directors (the “Board”) of Allena Pharmaceuticals, Inc. (the “Company”) since September 2011, informed the Board that he will not stand for reelection at the Company’s 2018 Annual Meeting of Stockholders, scheduled to be held on June 8, 2018 (the “Annual Meeting”). Accordingly, Mr. Kraus’ service as a member of the Board will cease following the Annual Meeting. Mr. Kraus’ decision not to stand for reelection is not a result of any disagreement with other Board members or with our management. The Company thanks Mr. Kraus for his service.
On April 25, 2018, as further described in the Company’s proxy statement filed on the date of this Current Report, the Board nominated Andrew A.F. Hack for election to the Board, as a member of Class I of the Board, at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: April 25, 2018 | Allena Pharmaceuticals, Inc. | |||||
| By: | /s/ Edward Wholihan | |||||
| Edward Wholihan | ||||||
| Chief Financial Officer | ||||||